In this article, we will list the 5 High Growth Healthcare Stocks to Buy Now. Please visit 11 High Growth Healthcare Stocks to Buy Now if you would like to see the extended list and the methodology behind it.

5. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is one of the best high growth healthcare stocks to buy now. Cantor Fitzgerald cut the price target on Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) to $31 from $35 on March 13, reiterating an Overweight rating on the shares and telling investors in a research note that it updated its model after the fiscal Q4 earnings report, which includes pruning estimates for both Syfovre and Empaveli.

In its fiscal Q4 and full year 2025 financial results, Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) reported net product revenues of $689 million for the full year 2025, with SYFOVRE® (pegcetacoplan injection) full year 2025 net product revenue of $587 million and EMPAVELI® (pegcetacoplan) full year 2025 net product revenue of $102 million. It also stated that the regulatory submission for SYFOVRE prefilled syringe is planned for the first half of 2026. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) has cash and cash equivalents of $466 million as of December 31, 2025, with projected revenues, cash, and cash equivalents anticipated to be sufficient to fund operations to profitability.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is a commercial-stage biopharmaceutical company that discovers, develops, and commercializes novel therapeutic compounds for treating diseases with unmet needs. Its product portfolio primarily includes EMPAVELI and SYFOVRE. SYFOVRE treats geographic atrophy secondary to age-related macular degeneration (GA), while EMPAVELI treats paroxysmal nocturnal hemoglobinuria (PNH).

4. Guardant Health, Inc. (NASDAQ:GH)

Guardant Health, Inc. (NASDAQ:GH) is one of the best high growth healthcare stocks to buy now. Guardant Health, Inc. (NASDAQ:GH) and Verana Health announced on March 24 a new partnership aimed at allowing biopharmaceutical researchers to access the combined resources of Guardant’s clinicogenomic testing data and Verana’s regulatory-grade, therapeutic-specific EHR curated datasets to expedite the development of new therapies and enhance ongoing patient care.

Management stated that the collaboration provides extensive datasets that would allow research scientists to easily understand and validate correlations between molecular biomarkers, treatment decisions, and clinical outcomes.

Craig Eagle, MD, Guardant Health, Inc. (NASDAQ:GH) chief medical officer, stated that the real-world data partnership with Verana marks a considerable milestone in the company’s mission to advance novel therapies, in particular cancer, with data. He added that allowing “biopharmaceutical researchers the ability to connect detailed information about tumor biology and therapy response with real-world patient outcome data” would accelerate the discovery of new biomarker-based therapies for patients, helping make the drug development process more economical.

Guardant Health, Inc. (NASDAQ:GH) is a precision oncology company specializing in treating cancer through vast data sets, proprietary blood-based tests, and advanced analytics. The company’s solutions include recurrence detection, early detection, and treatment selection.

3. Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is one of the best high growth healthcare stocks to buy now. Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) announced on March 24 a set of strategic efforts aimed at accelerating earlier recognition and improving care coordination for patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM). The company is advancing, through complementary initiatives with Viz.ai and the American Heart Association, a comprehensive, system‑level approach addressing the continuous challenges of underdiagnosis and fragmented care in ATTR‑CM.

In a separate development, Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) was downgraded to Hold from Buy by Jefferies on March 16. The firm also cut the price target on the stock to $330 from $522 after assuming coverage of the name, telling investors in a research note that it is “impressed” with the company’s RNAi platform. The firm said that it believes the shares are “priced to perfection”, adding that Alnylam Pharmaceuticals Inc.’s (NASDAQ:ALNY) longer-term consensus expectations are at risk as they price in big market growth and low competition.

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is a biopharmaceutical company that develops and commercializes novel therapeutics based on ribonucleic acid interference.

2. BridgeBio Pharma, Inc. (NASDAQ:BBIO)

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the best high growth healthcare stocks to buy now. Mizuho lifted the price target on BridgeBio Pharma, Inc. (NASDAQ:BBIO) to $106 from $91 on March 18, reiterating an Outperform rating on the shares and telling investors in a research note that the primary catalyst for the company this year is Pfizer’s tafamidis litigation bench trial from April 27 to May 5, which holds the potential to materially impact the stock. The firm added that it raised the price target based on factors such as the continued strength of Attruby, updated infigratinib data in achondroplasia and hypochondroplasia, and the potential upside from a favorable litigation outcome, which can add considerable value per $1 billion in peak sales.

In another development, BridgeBio Pharma, Inc. (NASDAQ:BBIO) was initiated with an Outperform rating on March 10 by William Blair, with a fair value estimate of $93.03 per share. The firm told investors in a research note that the company is a commercial-stage biotech in a “unique position”, with an accelerating launch in Attruby, regulatory submission for infigratinib in achondroplasia planned for the second half of 2026, and near-term new drug application submissions setting up late-2026 or early-2027 launches. Blair added that it sees Attruby to be well positioned for growth.

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a commercial-stage biopharmaceutical company that discovers, creates, tests, and delivers transformative medicines to treat patients suffering from genetic diseases and cancers.

1. Insmed Incorporated (NASDAQ:INSM)

Insmed Incorporated (NASDAQ:INSM) is one of the best high growth healthcare stocks to buy now. Stifel raised the price target on Insmed Incorporated (NASDAQ:INSM) to $208 from $205 on March 24, reaffirming a Buy rating on the shares. The firm told investors that it believes Phase 3b ENCORE results “should unequivocally establish” Arikayce as the new first-line standard-of-care therapy to treat lung infection caused by nontuberculous mycobacteria-mycobacterium avium complex. It added that the ENCORE results “appear a best-case scenario for Arikayce label expansion efforts.”

Insmed Incorporated (NASDAQ:INSM) reported full-year 2025 total revenues of $606.4 million, including BRINSUPRI revenues of $172.7 million for the year and $144.6 million in Q4. ARIKAYCE delivered $119.2 million in Q4 and $433.8 million for the full year, representing 19% annual growth and exceeding the upper end of guidance. The combination of accelerating commercial uptake and expanding market opportunity suggests that 2026 could mark a pivotal inflection point in revenue visibility and operating leverage.

Insmed Incorporated (NASDAQ:INSM) was founded in 1988. Headquartered in Bridgewater, New Jersey, Insmed is a global biopharmaceutical firm focused on developing and commercializing therapies for patients with rare and serious diseases, with key assets including brensocatib and Treprostinil Palmitil Inhalation Powder.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.